Chemomab Therapeutics Ltd.
CMMB
$1.74
-$0.03-1.70%
NASDAQ
| 12/31/2025 | 06/30/2025 | 12/31/2024 | 09/30/2024 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | 3.41M | 3.36M | 11.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | 14.74M | 15.37M | 32.26M |
| Operating Income | -- | -- | -14.74M | -15.37M | -32.26M |
| Income Before Tax | -- | -- | -13.95M | -14.40M | -31.81M |
| Income Tax Expenses | -- | -- | -- | -- | -513.00K |
| Earnings from Continuing Operations | -- | -- | -13.95 | -14.40 | -31.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -13.95M | -14.40M | -31.30M |
| EBIT | -- | -- | -14.74M | -15.37M | -32.26M |
| EBITDA | -- | -- | -14.68M | -15.31M | -32.20M |
| EPS Basic | -- | -- | -282.21 | -315.95 | -55.51 |
| Normalized Basic EPS | -- | -- | -1.03 | -1.29 | -1.76 |
| EPS Diluted | -- | -- | -282.21 | -315.95 | -55.51 |
| Normalized Diluted EPS | -- | -- | -1.03 | -1.29 | -1.76 |
| Average Basic Shares Outstanding | -- | -- | 16.23M | 14.76M | 45.16M |
| Average Diluted Shares Outstanding | -- | -- | 202.60K | 184.30K | 2.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |